| Literature DB >> 32161895 |
Abstract
OBJECTIVE: Irrigant activation has been claimed to be beneficial in in vitro and clinical studies. This systematic review aims to investigate the clinical efficiency of mechanically activated irrigants and conventional irrigation.Entities:
Keywords: Active irrigation; EndoActivator; EndoVac; continuous ultrasonic irrigation; manual dynamic agitation; passive ultrasonic irrigation; ultrasonic irrigation
Year: 2019 PMID: 32161895 PMCID: PMC7006592 DOI: 10.14744/eej.2019.80774
Source DB: PubMed Journal: Eur Endod J ISSN: 2548-0839
PRISMA Checklist
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| TITLE | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| ABSTRACT | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2; Separate document |
| INTRODUCTION | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 6 |
| METHODS | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 7 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 8 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 8 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 8 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 9 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 9 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 9 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 10 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 10 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective within studies). | 10 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 10 |
| RESULTS | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 11 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 11 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 11 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 11 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 11 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 12 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | 12 |
| DISCUSSION | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 12 |
| Limitations | 25 | Discuss limitations at study and outcomelevel (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 18 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 19 |
| FUNDING | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 19 |
Figure 1PRISMA 2009 Flowchart
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097
Study details of articles included in data synthesis
| S. no: | Author/year | Sample size | Devices tested | Control used | Parameters evaluated (variables of interest) | Methodology |
|---|---|---|---|---|---|---|
| 1 | Haidet et al. 1989 | 60 | CaviEndo- Ultrasonic | Standard syringe | Canal & Isthmus Cleanliness | Histological preparation after sectioning of apical 1-3mm; Gomori’s one step trichrome method of staining; |
| 2 | Archer et al. 1992 | 42 | EnacOsada- Ultrasonic | Standard syringe | Canal & Isthmus Cleanliness | Histological preparation after sectioning of apical 1-3mm; 5µ sections; 0.1mm interval; Gomori’s one step trichrome method of staining; |
| 3 | Gutarts et al. 2005 | 36 | MiniEndo- Ultrasonic | Standard syringe | Canal & Isthmus Cleanliness | Histological preparation after sectioning of apical 1-3mm; 5µ sections; 0.2mm interval; Gomori’s one step trichrome method of staining; |
| 4 | Burleson et al. 2007 | 48 | Ultrasonic needle- Mini Endo unit with Aladdin mechanical pump | Syringe (not specified) with Aladdin mechanical pump | Canal and isthmus cleanliness | Histologic preparation and Brown & Brenn staining of cross-sections from the 1-3 mm apical levels; 5µ sections; 0.2mm interval; evaluated for percentage of biofilm/ necrotic debris removal. |
| 5 | Carver et al. 2007 | 31 | MiniEndo- Ultrasonic | Standard syringe | Antibacterial efficacy | Brucella Blood Agar; Anaerobic chamber; CFU counting using operating microscope |
| 6 | Huffaker et al. 2010 | 84 | Endo Activator | Syringe with 27 Gauge side vent needle | Anti-bacterial efficacy | Anaerobic tube turbidity test at 1 week using bacteriologic sampling of root canals. |
| 7 | Gondim et al. 2010 | 110 | EndoVac | Max-I-probe | Post-Operative Pain | Pain levels were assessed at 4h, 24h and 48h according to Borg scale 0-10. |
| 8 | Siu et al. 2010 | 47 | EndoVac | Syringe (not specified) | Debridement efficacy | Six histological slides of each 6μm thickness were made from sections at 1 and 3 mm from WL and stained. The slide with the most debris was photographed at each level for each tooth. Median amount of debris at 1mm and 3 mm were assessed. |
| 9 | Munoz et al. 2012 | 30 | EndoVac, PUI- IrriSafe | Monoject syringe | Delivery of irrigant to working length (WL) of root canals | Canals were irrigated with 1 ml of IOHEXOL (radiopaque solution) by using the assigned irrigation systems was done and a digital radiograph was taken. With the aid of image editing software the distance between WL and maximum irrigant penetration was measured. |
| 10. | Pawar et al. 2012 | 52 | EndoVac | Syringe with 27-gauge side vented Monoject stainless steel needle | Anti-bacterial efficacy | Anaerobic tube turbidity test at 1 week using bacteriologic sampling of root canals |
| 11. | Paiva et al. 2012 Liang et al. 2013 | 105 | PUI Ultrasonic activation | 2% CHX in NaviTip syringe NaviTip 30 Gauge needle | Antibacterial efficacy Radiographic evaluation of periapical healing | Culturing & PCR; bacteria, archaea & fungi; |
| 12. | Liang et al. 2013 | 105 | Ultrasonic activation | NaviTip 30 Gauge needle | Radiographic evaluation of periapical healing | Ten to 19 months after treatment, the teeth were examined by using Periapical radiography and CBCT. Absence and reduction of the periapical radiolucency were analyzed. |
| 13. | Ramamoorthy et al. 2015 | 110 | Endo Activator | Syringe with 27 gauge open ended needle | Post-Operative Pain | Pain levels were assessed according to Visual Analogue Scale (VAS). Score (Range 0-7) at 8h, 24h and 48h. |
| 14. | Tang et al. 2015 | 300 | Ultrasonic activation | Syringe (not specified) | Post-Operative Pain and Periapical healing through radiographic follow up | Pain levels were assessed at 24 hours, 6months and 12 months after irrigation protocol according to VAS. Score 0-3. Clinical effective rates were calculated according to PAI (Peri apical index) and Clinical examination |
| 15. | Middha et al. 2017 | 70 | CUI- ProultraPiezoflow | 27 gauge needle | Post-operative pain | VAS scale; every day for 1-7days; |
| 16. | Topcuoglu et al. 2018 | 116 | EndoVac | NaviTip syringe | Post-operative pain | VAS scale; 6, 24, 48 & 72h; 1 week; |
| 17. | Topcuoglu et al. 2018 | 168 | EndoActivator, PUI & MDA | NaviTip syringe with side-port needle | Post-operative pain | VAS scale; 6, 24, 48 & 72h; 1 week; |
Description of the devices tested in this review
| Name of the devices | Manufacturer | Description of mechanism of action |
|---|---|---|
| Ultrasonic Activation- CaviEndo | Dentsply International/York/PA/.USA | First ultrasonic unit designed for both prophylaxis and endodontics. It is a magnetostrictive ultrasound unit. It has a switch, prophy/endo mode selection switch, power control dial with LED indicators, water supply control dial with LED indicators, Air pressure valve window. |
| Ultrasonic Activation- OsadaEnac | ENAC/USA | It’s an ultrasonic endodontic system based on Quartz Piezoelectric vibrator system. It is automatically tuned to provide stable 30KHz ultrasonic oscillation. It has a handpiece-hose assembly, handpiece holder, footswitch, water hose with filter & connector. Simultaneous root canal enlargement with U files and swirling irrigation for debridement, root canal obturation without water, restoration removal, flush cleaning of periodontal pockets and pits& fissures, root-end preparations with angled diamond coated files are the functions of this unit. |
| CUI- Ultrasonic Activation- Proultra PiezoFlow | Dentsply Tulsa Dental Specialties, Tulsa, OK/USA | This unit is designed to deliver continuous irrigation. It provides superior cleaning power by facilitating introducing irrigants into root canal structure, dentinal tubules & isthmuses. It can disrupt biofilms. It enhances the action of NaOCl even if applied for 1min. |
| Ultrasonic Activation- Mini Endo Unit | SybronEndo/USA/ | The MiniEndo II is a compact ultrasonic cleaning unit designed specifically for endodontic applications. It is operated and controlled by microprocessors designed to deliver just the right amount of power and amplitude at the tip to successfully complete endodontic procedures. |
| PUI- IrriSafe | Satelec (R&D), France | Its exclusive design helps to remove the smear-layer and to kill the bacteria, even in difficult-to-reach areas (apical third) or in curved canals. It can be used safely, without any risk of damaging the apical structure. Driven by the Newtron range of piezoelectric generators, IrriSafe generates micro-cavitation and micro- currents that spread through the canal system. The thinnest diameter is recommended for the majority of the clinical cases (IRR 20), the largest instrument can be used for the treatment of juvenile canals (IRR 25). The instrument should vibrate freely inside the root canal lumen. IrriSafe is available in two lengths, from IRR20/21 or IRR20/25 and, IRR25/21 or IRR25/25. IrriSafe is inserted 2 mm short of the working-length and it can be pre-shaped, if necessary. 20 ml of the irrigant solution is injected into the canal with a syringe. IrriSafe is activated for 10 seconds, at the recommended color coded power level moving the instrument with a ¼-pull-stroke and backwards: it drives the debris and the smear layer back to the surface. |
| MDA | NA | This is not a gadget, but a method of manually activating irrigant using GP cones with 100 push/ pull/min amplitude. |
| EndoActivator | Dentsply Tulsa Dental Specialties, Tulsa, OK/USA | The EndoActivator is designed to safely and vigorously energize intracanal irrigants using sonic energy. It has strong, flexible medical grade uncoated & non cutting polymer tips for Single patient use. It creates fluid hydrodynamics, improves debridement and the disruption of the smear layer and biofilm |
| EndoVac | Discus Dental, Culver City, CA | The EndoVac system is regarded as an apical negative pressure irrigation system composed of three basic components: A Master Delivery Tip (MDT), the Macrocannula, and the Microcannula. The MDT delivers irrigant to the pulp chamber and evacuates the irrigant concomitantly. Both the macrocannula and microcannula are connected via tubing to a syringe of irrigant and the highspeedsuction of a dental unit. The Macrocannula is made of sflexible polypropylene with an open end of 0.55 mm in diameter, an internal diameter of 0.35 mm, and a 0.02 taper, used to suction irrigants up to the middle segment of the canal. Lastly, the Microcannula is made of stainless steel and has 12 microscopic holes disposed in four rows of three holes, laterally positioned at the apical 1 mm of the cannula. Each hole is 0.1 mm in diameter, the first one in the row is located 0.37 mm from the tip of the microcannula, and the distance between holes is 0.2 mm. The microcannula has a closed end with external diameter of 0.32 mm can be used in canals that are enlarged to size 35 or larger, and should be taken to the working length (WL) to aspirate irrigants and debris. During irrigation, the MDT delivers irrigant to the pulp chamber and siphons off the excess irrigant to prevent overflow. The cannula in the canal simultaneously exerts negative pressure that pulls the irrigant from its fresh supply in the chamber by the MDT, down the canal to the tip of the cannula, into the cannula, and out through the suction hose. Thus, a constant flow of fresh irrigant is being delivered by negative pressure to working length. |
Major criteria for Risk of bias assessment for selected articles
| S. No: | Reference | Method of randomization | Allocation concealment | Blinding | Drop out rate |
|---|---|---|---|---|---|
| 1 | Haidet et al. 1989 | Yes | Not mentioned | Single | NA; 1.7% due to loss of tooth during sectioning |
| 2 | Archer et al. 1992 | Yes | Not mentioned | Not mentioned | No drop-out |
| 3 | Gutarts et al. 2005 | Yes | Not mentioned | Single | No drop-out |
| 4 | Burleson et al. 2007 | Yes | No | Single | No drop-out |
| 5 | Carver et al. 2007 | Yes | Not mentioned | Single | No drop-out |
| 6 | Gondim et al. 2010 | Yes | Yes | Double | No drop-out |
| 7 | Huffaker et al. 2010 | Yes | No | Double | NA; 11.9% due to loss of tooth during sectioning |
| 8 | Siu et al. 2010 | Yes | No | Single | No |
| 9 | Munoz et al. 2012 | No | No | No | No |
| 10. | Pawar et al. 2012 | Yes | Yes | Single | No |
| 11. | Paiva et al. 2012 | Yes | No | Not mentioned | 6.25% |
| 12. | Liang et al. 2013 | Yes | No | No | No |
| 13. | Ramamoorthi et al. 2015 | Yes | Yes | Single | Yes |
| 14. | Tang et al. 2015 | No | No | No | No |
| 15. | Middha et al. 2017 | Yes | Yes | Not mentioned | No drop-out |
| 16. | Topcuoglu et al. 2018 | Yes | Not mentioned | Single | 2.6% |
| 17. | Topcuoglu et al. 2018 | Yes | Not mentioned | Single | No drop-out |
Minor criteria for Risk of bias assessment for selected articles
| S. No: | Reference | Sample justified | Baseline comparison | Inclusion/exclusion criteria | Method error |
|---|---|---|---|---|---|
| 1 | Haidet et al. 1989 | Yes | Yes | Yes | No |
| 2 | Archer et al. 1992 | Yes | Yes | Yes | No |
| 3 | Gutarts et al. 2005 | Yes | Yes | Yes | No |
| 4. | Burleson et al. 2007 | No | Not applicable | Yes | No |
| 5 | Carver et al. 2007 | Yes | Yes | Yes | No |
| 6. | Siu et al. 2010 | No | Not applicable | Yes | No |
| 7. | Huffaker et al. 2010 | No | Yes | Yes | No |
| 8. | Gondim et al. 2010 | Yes | Yes | Yes | No |
| 9. | Munoz et al. 2012 | No | Yes | Yes | No |
| 10. | Pawar et al. 2012 | No | Yes | Yes | No |
| 11. | Paiva et al. 2012 | Yes | Yes | Yes | No |
| 12. | Liang et al. 2013 | No | Yes | Yes | No |
| 13. | Ramamoorthi et al. 2015 | Yes | Yes | Yes | No |
| 14. | Tang et al. 2015 | No | Yes | Yes | No |
| 15. | Middha et al. 2017 | Yes | Yes | Yes | No |
| 16. | Topcuoglu et al. 2018 | Yes | Yes | Yes | No |
| 17. | Topcuoglu et al. 2018 | Yes | Yes | Yes | No |
Outcome assessment
| Author | Variables of Interest assessed | Evaluation period for outcome assessment & Outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Immediate | 4h | 8h | 24h | 2W | 6 Mo | 10-19 Mo | 12 Mo | ||||
| Haidet et al. 1989 | Canal cleanliness Isthmus cleanliness | 1mm- Ultrasonic>Syringe 3mm-Ultrasonic=Syringe 1&3mm- Ultrasonic> Syringe | |||||||||
| Archer et al. 1992 | Canal cleanliness Isthmus cleanliness | Ultrasonic>Syringe | |||||||||
| Gutarts et al. 2005 | Canal cleanliness Isthmus cleanliness | 1mm- Ultrasonic>Syringe 3mm-Ultrasonic=Syringe 1&3mm-Ultrasonic> Syringe | |||||||||
| Burleson et al. 2007 | Canal cleanliness | syringe vs. ultrasonic 1mm: 33% vs. 83%; 2mm: 31% vs. 86%; 3mm: 45% vs. 91%. | |||||||||
| Isthmus cleanliness | 1mm: 80% vs. 95%; 2mm: 92% vs. 99%; 3mm: 95% vs. 100% | ||||||||||
| Carver et al. 2007 | Antibacterial efficacy | Ultrasonic – 80%-ve culture; Syringe–20% -ve culture CFU-Ultrasonic<Syringe | |||||||||
| Siu et al. 2010 | Median amount of debris | 3mm: EV: 0.09% S: 0.07%. 1mm: EV: 0.05% S: 0.12% | |||||||||
| Huffaker et al. 2010 | Cultivable bacteria | S: 52% EA : 60% | |||||||||
| Gondim et al. 2010 | Post-operative pain (Borg) | MP: 1.72 EV: 0.39 | MP: 1.45 EV: 0.31 | MP: 0.50 EV: 0.18 | |||||||
| Munoz et al. 2012 | Mean distance from irrigant delivery to WL | M: 1.51 +- 0.43 mm EV: 0.42 +-0.30 mm PUI: 0.21+-0.25 mm | |||||||||
| Pawar et al. 2012 | Microbial growth | EV: 17.4% S: 9.1 % | |||||||||
| Paiva et al. 2012 | Antimicrobial efficacy | Culture- CHX Syringe -14% +ve; PUI–23% +ve; PCR- CHX Syringe-43% +ve; PUI–54% +ve; | |||||||||
| Liang et al. 2013 | Reduction of lesion | Ultrasonic 95.1 % Syringe 88.4%. | |||||||||
| Ramamoorthy et al. 2015 | Post-operative pain (VAS) Mean pain score | EN: 5.4 EA: 3.7 | EN: 3.1 EA: 1.4 | EN: 0.8. EA: 0.3 | |||||||
| Tang et al. 2015 | Post-operative pain (VAS & customized grading) | Ultrasonic with NaOCl: (n=120): 0 (n=99); 1 (n=15), 2 (n=4), 3 (n=2) Ultrasonic with Active Ag++: (n=122): 0 (n=103), 1 (n=14), 2 (n=4), 3 (n=1) Syringe: (n=188): 0 (n=71), 1(n=26), 2 (n=17), 3(n=4) | |||||||||
| Clinical effective rates according to PAI: | Ultrasonic with NaOCl: 80.83% Ultrasonic with Active Ag++: 81.15% Syringe: 74.58% | Ultrasonic with NaOCl:85% Ultrasonic with Active Ag++: 88.52% Syringe: 77.97% | |||||||||
| Middha et al. 2017 | Post-operative pain | CUI – 31% Syringe – 51% | No difference | No difference | No difference | ||||||
| Topcuoglu et al. 2018 | Post-operative pain | 6h: Syringe>EV | 24h: Syringe>EV | 48h: Syringe>EV | 72h: No difference | 1w: No difference | |||||
| Topcuoglu et al. 2018 | Post-operative pain | 6h: MDA>other groups | 24h: MDA>other groups | 48h: No difference | 72h: No difference | 1w: No difference | |||||
EN: Endodontic needle, EA: EndoActivator, NaOCl: Sodium hypochlorite, VAS: Visual analog scale, PAI: Periapical index, MP: Max I probe, S: Syringe, M: Monoject, PUI: Passive ultrasonic irrigation, MDA: Manual dynamic agitation, CUI: Continuous ultrasonic irrigation
Risk of bias and quality assessment across studies
| S. No: | Reference | Randomization | Allocation concealment | Blinding | Inclusion/ exclusion criteria | Completeness of follow up | Sample size calculation | CEBM Level of evidence | Risk of bias Cumulative risk (Average of Major and Minor criteria) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Haidet et al. 1989 | Yes | No | No | Yes | NA | Not mentioned | 2 | 3 (high) |
| 2 | Archer et al. 1992 | Yes | No | No | Yes | NA | Not mentioned | 2 | 3 (high) |
| 3 | Gutarts et al. 2005 | Yes | No | No | Yes | NA | Not mentioned | 2 | 3 (high) |
| 4 | Burleson et al. 2007 | Yes | No | Yes | Yes | NA | Not mentioned | 2 | 2 (moderate) |
| 5 | Carver et al. 2007 | Yes | No | No | Yes | NA | Not mentioned | 2 | 3 (high) |
| 6 | Siu et al. 2010 | Yes | No | Yes | Yes | NA | Not mentioned | 2 | 2 (moderate) |
| 7 | Huffaker et al. 2010 | Yes | No | No | Yes | NA | Mentioned | 2 | 2 (moderate) |
| 8 | Gondim et al. 2010 | Yes | Yes | Yes | Yes | Yes | Mentioned | 2 | 1 (low) |
| 9 | Munoz et al. 2012 | No | No | No | Yes | NA | Not mentioned | 3 | 3 (high) |
| 10. | Pawar et al. 2012 | Yes | Yes | Yes | Yes | NA | Not mentioned | 2 | 1 (low) |
| 11. | Paiva et al. 2012 | Yes | No | No | Yes | NA | Not mentioned | 2 | 3 (high) |
| 12. | Liang et al. 2013 | Yes | No | No | Yes | Yes | Not mentioned | 2 | 2 (moderate) |
| 13. | Ramamoorthi et al. 2015 | Yes | Yes | Yes | Yes | Yes | Mentioned | 2 | 1(low) |
| 14. | Tang et al. 2015 | No | No | No | Yes | Yes | Not mentioned | 3 | 3 (high) |
| 15. | Middha et al. 2017 | Yes | Yes | Yes | Yes | Yes | Mentioned | 2 | 1 (low) |
| 16. | Topcuoglu et al. 2018 | Yes | Yes | Yes | Yes | Yes | Mentioned | 2 | 1 (low) |
| 17. | Topcuoglu et al. 2018 | Yes | Yes | Yes | Yes | Yes | Mentioned | 2 | 1 (low) |
CEBM: Centre for Evidence-based medicine, NA: Not applicable